ReviewCancer gene therapy2025
Promoting the therapeutic potential of interleukin-7 (IL-7) by expression in viral vectors.
Review in Cancer gene therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Innovative biomaterial solutions for enhancing the efficacy of tumor immunotherapy.Immunologic research · 2026Review
- Advances in IL-2 Family Cytokine-Based Cancer Therapies: Overcoming Challenges Through Molecular Engineering and Delivery Strategies.Immune network · 2026Review
- Review
- IL-7: a potential next-generation adjuvant for immune cell therapies.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Interleukin 7 (IL-7) is an immunostimulatory cytokine essential for T cell development, proliferation, and maintenance. While IL-7 generates antitumor immunity, systemic IL-7 has not consistently produced strong anticancer effects. Achieving therapeutic cytokine concentrations in tumors often requires high systemic doses, leading to toxicity. To address this, localized cytokine expression within the tumor microenvironment (TME) has gained interest. One such approach involves cytokine expression by oncolytic viruses (OVs) that selectively replicate in cancerous cells while sparing 'normal' cells. Additionally, non-replicative viral vectors have become valuable tools for sustaining cytokine expression in the TME, inducing antitumor effects through non-lytic mechanisms. To effectively harness IL-7's antitumor potential, both oncolytic and non-lytic viruses have been engineered to express IL-7, either alone or in combination with other immunomodulators, such as IL-12, IL-15, B7-1, or CCL19. Despite promising advancements, no comprehensive review exists on IL-7 expression in virus-based immunotherapy for cancer. Therefore, this manuscript aims to (i) summarize studies on viral IL-7 expression alone or with other immunomodulators, (ii) discuss the associated immune mechanisms of action, and (iii) explore opportunities for co-expressing IL-7 with other key cytokines to optimize immunovirotherapy strategies for cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.